帕博利珠单抗联合R-CHOP一线治疗初治弥漫大B细胞淋巴瘤
在30例初治DLBCL患者中评估帕博利珠单抗联合R-CHOP的安全性,毒性总体与标准R-CHOP相当,出现2例≥3级免疫相关不良事件;PD-L1表达与非GCB亚型相关,并与改善的PFS和生存相关。
要点
- 帕博利珠单抗联合R-CHOP在初治DLBCL中安全性可接受。
- 该方案总缓解率90%、完全缓解率77%、2年PFS 83%。
- PD-L1表达与非GCB亚型及改善的PFS和生存相关。
核心结论
- 帕博利珠单抗可安全加入R-CHOP,并伴高完全缓解率和2年PFS。
研究设计与样本
- 评估初治DLBCL患者中帕博利珠单抗联合R-CHOP的毒性,纳入30例年龄≥18岁、器官功能充足、需全程治疗的患者。
主要发现
- 毒性总体与标准R-CHOP相当,但发生2例≥3级免疫相关不良事件(皮疹、肺炎)。
- 总缓解率为90%,完全缓解率为77%。
- PD-L1表达与非GCB亚型相关,并与改善的PFS和生存相关。
关键数值与推荐
- 帕博利珠单抗剂量为200 mg/周期,联合R-CHOP。
- PD-L1染色在经验证的中央实验室进行。
临床怎么用
- 帕博利珠单抗联合R-CHOP可作为初治DLBCL的潜在治疗选择。
- PD-L1表达可能作为生物标志物筛选可从一线该策略获益的DLBCL患者。
局限性
- 样本量较小(30例),需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tumor programmed death-ligand 1 (PD-L1) expression in diffuse large B-cell lymphoma (DLBCL) is associated with inferior outcomes. The first-line immunologically-replete setting may be an opportune time for PD-1 inhibition. We evaluated pembrolizumab in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in untreated patients with DLBCL. Eligible patients were age 18 or older, had adequate organ function, and had DLBCL requiring full-course therapy. Patients received pembrolizumab 200 mg/cycle with R-CHOP, primarily to assess toxicity. Response assessment utilized standard criteria, and PD-L1 staining was performed at a validated central laboratory. Among 30 patients, toxicity was comparable to standard R-CHOP but with two grade ≥3 immune related adverse events (rash, pneumonitis). The overall and complete response rate was 90% and 77%. With 25·5 months of median follow-up, 2-year progression-free survival (PFS) is 83%. PD-L1 expression was associated with non-GCB subtype, and improved PFS and survival. Pembrolizumab can safely be added to R-CHOP, and is associated with a high CR rate and 2-year PFS. Improved PFS with PR-CHOP in PD-L1 expressing tumors contradicts historical data in R-CHOP treated patients, supporting evaluation of PD-L1 as a biomarker to identify DLBCL patients who may benefit from this first-line strategy.
引用
- Smith SD, Till BG, Shadman MS, et al. Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. Br J Haematol. 2020. PMID: 32030732. doi:10.1111/bjh.16494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。